Feb 12, 2026
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home SettingVIEW RELEASE
Jan 20, 2026
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home SettingVIEW RELEASE
Jan 12, 2026
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home SettingVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Feb 13, 2026 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.58
CHANGE
0.04 (2.6%)
